138 related articles for article (PubMed ID: 17330105)
21. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
22. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.
Lee BH; Williams IR; Anastasiadou E; Boulton CL; Joseph SW; Amaral SM; Curley DP; Duclos N; Huntly BJ; Fabbro D; Griffin JD; Gilliland DG
Oncogene; 2005 Nov; 24(53):7882-92. PubMed ID: 16116483
[TBL] [Abstract][Full Text] [Related]
23. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.
Levis M; Pham R; Smith BD; Small D
Blood; 2004 Aug; 104(4):1145-50. PubMed ID: 15126317
[TBL] [Abstract][Full Text] [Related]
24. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
Nishioka C; Ikezoe T; Yang J; Takeshita A; Taniguchi A; Komatsu N; Togitani K; Koeffler HP; Yokoyama A
Leuk Res; 2008 Jun; 32(6):865-72. PubMed ID: 17983653
[TBL] [Abstract][Full Text] [Related]
25. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
26. [Sensitivity of AML Cells with FLT3
Wang YY; Liu CY; Zhang W; He JJ; Su L; Sun WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1350-1355. PubMed ID: 29070106
[TBL] [Abstract][Full Text] [Related]
27. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Levis M; Brown P; Smith BD; Stine A; Pham R; Stone R; Deangelo D; Galinsky I; Giles F; Estey E; Kantarjian H; Cohen P; Wang Y; Roesel J; Karp JE; Small D
Blood; 2006 Nov; 108(10):3477-83. PubMed ID: 16857987
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
[TBL] [Abstract][Full Text] [Related]
29. Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells.
Rörby E; Adolfsson J; Hultin E; Gustafsson T; Lotfi K; Cammenga J; Jönsson JI
Exp Hematol Oncol; 2021 Feb; 10(1):7. PubMed ID: 33531064
[TBL] [Abstract][Full Text] [Related]
30. FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.
Català A; Pastor-Anglada M; Caviedes-Cárdenas L; Malatesta R; Rives S; Vega-García N; Camós M; Fernández-Calotti P
Oncotarget; 2016 Aug; 7(31):49786-49799. PubMed ID: 27391351
[TBL] [Abstract][Full Text] [Related]
31. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.
Yao Q; Weigel B; Kersey J
Clin Cancer Res; 2007 Mar; 13(5):1591-600. PubMed ID: 17332306
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Strati P; Kantarjian H; Ravandi F; Nazha A; Borthakur G; Daver N; Kadia T; Estrov Z; Garcia-Manero G; Konopleva M; Rajkhowa T; Durand M; Andreeff M; Levis M; Cortes J
Am J Hematol; 2015 Apr; 90(4):276-81. PubMed ID: 25530214
[TBL] [Abstract][Full Text] [Related]
33. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of gilteritinib in combination with chemotherapy in preclinical models of
Ueno Y; Mori M; Kamiyama Y; Saito R; Kaneko N; Isshiki E; Kuromitsu S; Takeuchi M
Oncotarget; 2019 Apr; 10(26):2530-2545. PubMed ID: 31069015
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Armstrong SA; Kung AL; Mabon ME; Silverman LB; Stam RW; Den Boer ML; Pieters R; Kersey JH; Sallan SE; Fletcher JA; Golub TR; Griffin JD; Korsmeyer SJ
Cancer Cell; 2003 Feb; 3(2):173-83. PubMed ID: 12620411
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
37. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
Kiyoi H; Shiotsu Y; Ozeki K; Yamaji S; Kosugi H; Umehara H; Shimizu M; Arai H; Ishii K; Akinaga S; Naoe T
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4575-82. PubMed ID: 17671144
[TBL] [Abstract][Full Text] [Related]
38. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
39. FLT3 mutations: biology and treatment.
Small D
Hematology Am Soc Hematol Educ Program; 2006; ():178-84. PubMed ID: 17124058
[TBL] [Abstract][Full Text] [Related]
40. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Muccioli G; Viola A; Pane F; Palmieri S
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1018-24. PubMed ID: 20172040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
